Search

Displaying results 2181 - 2190 of 2489 in total
  1. Drug

    Vinpocetine

    go.drugbank.com/drugs/DB12131
    Investigational

    Vinpocetine has been investigated for the treatment of Epilepsy.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    BMS-275183

    go.drugbank.com/drugs/DB12144
    Investigational

    BMS-275183 has been used in trials studying the treatment of Tumors and Non-small Cell Lung Cancer.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    Landiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine. It works to reduce the heart rate, myocardial contractility, and conduction v...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  4. Drug

    MK-0777

    go.drugbank.com/drugs/DB12238
    Investigational

    MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.

    Categories: Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 Substrates
  5. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Benzbromarone

    go.drugbank.com/drugs/DB12319
    ApprovedWithdrawn

    Benzbromarone has been used in trials studying the basic science and treatment of Heart Failure, Hyperuricemia, Chronic Kidney Disease, Abnormal Renal Function, and Gout and Asymptomatic Hyperuricemia.

    Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  7. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its fa...

    Categories: P-glycoprotein substrates
  8. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphi...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  9. Drug

    Indirubin

    go.drugbank.com/drugs/DB12379
    Investigational

    Indirubin is under investigation in clinical trial NCT01735864 (Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  10. Drug

    Lisofylline

    go.drugbank.com/drugs/DB12406
    Investigational

    Lisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates